ScripEli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripAtara Biotherapeutics is putting the key back in the ignition for Ebvallo (tabelecleucel) as the US Food and Drug Administration has lifted the clinical hold that it placed on the program in January,